|
 |
|
|
SCIENCE NEWS
'Junk DNA' Could Spotlight Breast and Bowel Cancer
Scientists at The University of Nottingham have found that a group of genetic rogue elements, produced by DNA sequences commonly known as 'junk DNA', could help diagnose breast and bowel cancer. [The University of Nottingham, Nottingham]
Lombardi Researchers Find Investigational Agent Reduces Tumor Resistance to Breast Cancer Therapy
Researchers have found a way to cleverly override signals that tell breast cancer cells to keep surviving in the face of anticancer treatment. [Georgetown University, Washington, DC]
Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
Bionovo, Inc. announced the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, describe the potential molecular mechanisms mediating the selective pro-apoptotic effect induced by BN107 on estrogen receptor negative breast cancer cells. [Bionovo, Inc., Emeryville]
|
|
CURRENT PUBLICATIONS
LABORATORY RESEARCH
Complex Landscapes of Somatic Rearrangement in Human Breast Cancer Genomes
The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development. [Nature]
CXCR1 Blockade Selectively Targets Human Breast Cancer Stem Cells in vitro and in Xenografts
Scientists report the development of a strategy to target breast cancer stem cells through blockade of the IL-8 receptor CXCR1. [J Clin Invest]
Aldehyde Dehydrogenase 1 - Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer
Results suggest that the metastatic, aggressive behavior of inflammatory breast cancer may be mediated by a cancer stem cell component that displays aldehyde dehydrogenase enzymatic activity. [Clin Cancer Res]
Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis
Researchers show the integrated roles of the antiapoptotic BCL-W and BCL2 in affecting responsiveness to the antiestrogen ICI 182,780 (ICI; Fulvestrant Faslodex), using both molecular (siRNA; shRNA) and pharmacologic (YC137) approaches in three breast cancer variants. [PLoS ONE]
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
An elevated level of the receptor tyrosine kinase Eph receptor A2 was found to be an important contributor to trastuzumab resistance. [Cancer Res]
Investigating AP-2 and YY1 Protein Expression as a Cause of High HER2 Gene Transcription in Breast Cancers with Discordant HER2 Gene Amplification
Candidacy for anti-HER2 adjuvant therapy in breast cancer is assessed using tumour HER2 status but recently it has been proposed that the transcription factors AP-2alpha and YY1 may cause HER2 protein overexpression independently of gene amplification. [Breast Cancer Res]
CLINICAL RESEARCH
Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Trastuzumab, docetaxel and capecitabine, when taken together, is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids. [J Clin Oncol]
A Randomized Phase II Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer
The 96-hour paclitaxel regimen did not significantly improve response or time to disease progression, was more cumbersome to administer, and was associated with greater myelosuppression (but less neuropathy and myalgia) compared with the 3-hour schedule. [Cancer]
|
|
EVENTS
BIT's 3rd Annual World Cancer Congress 2010 - Breast Cancer Conference
April 25-27, 2010
Shanghai, China
IMPAKT Breast Cancer Conference
May 6-8, 2010
Brussels, Belgium
Breast Cancer Research 2010 Conference
May 18, 2010
London, United Kingdom
Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy
12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy
The 21st Meeting of the European Association for Cancer Research
June 26-29, 2010
Oslo, Norway
Visit
our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Research & Development Scientist - Pancreatic Cell Biology (STEMCELL Technologies)
Research & Development Scientist - Endothelial Cell Biology (STEMCELL Technologies)
Research & Development Scientist - Epithelial Cell Biology (STEMCELL Technologies)
Data Entry Assistant - Marketing (STEMCELL Technologies)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
Visit here to post your career opportunities.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!
|
|
|
|
|
|
|
|
 |
